In medical news--
Sanofi says Libtayo reduced death risk by 32% compared
to chemotherapy in trial
Yikes usually it's vs placebo everybody hates Chemo is this a pill??????
14:16 SNY Pivotal trial data for the investigational use of PD-1 inhibitor Libtayo in first-line locally advanced or metastatic non-small cell lung cancer, or NSCLC, were shared in a presentation at the European Society for Medical Oncology, or ESMO, Virtual Congress 2020, Sanofi announced. The trial compared Libtayo
monotherapy to platinum-doublet chemotherapy in patients whose tumor cells expressed PD-L1, including those whose cancers had confirmed PD-L1 expression of greater than or equal to 50%. These results form the basis of regulatory submissions, including in the U.S. and European Union. The late-breaking ESMO presentation expands on topline results shared in April.
In the overall trial population of 710 patients, the median follow-up was 13 months for both Libtayo and chemotherapy. Among these patients, Libtayo demonstrated the following results compared to chemotherapy:
32% reduced risk of death; 22-month median overall survival compared to 14 months; 41% reduced risk of disease progression; and 37% objective response rate.
In the Education market-
Chegg call volume above normal and directionally bullish 13:45 CHGG Bullish option flow detected in Chegg with 4,685 calls trading, 1.1x expected, and implied vol increasing over 3 points to 59.64%. Oct-20 70 calls and Oct-20 75 calls are the most active options, with total volume in those strikes near 2,300 contracts. The Put/Call Ratio is 0.34.
Earnings are expected on November 2nd.
Scientific Games gets upgrade, Street-high target after structural changes-Ayyyyyy Carumba!
Sep. 21, 2020 3:35 PM ET|About:
Scientific Games Corporation (SGMS)
Last week, a group of institutional investors that
included Caledonia bought a 34.9% stake in Scientific Games(NASDAQ:
SGMS). The former CEO and CFO of gaming
company Aristocrat were also added to the SGMS board.
Jefferies is now upgrading Scientific Games from Hold to Buy, saying the ownership and leadership changes could drive "value creation
not seen in 20 years."
Analyst David Katz thinks SGMS could pursue deconsolidation by separating the tech business from traditional gaming, selling the SciPlay stake, or using SciPlay to raise capital, which could all imply a 20-25% upside to his price target.<---??????
Katz lifts his base case
from $20 to a Street-high price target of $50. The upside case is
$75, OH VAN! and the downside case is $16.
SGMS shares are up 2.1% to $33.64.<--- Why do I think the downside case of $14 will be the outcome for me if i buy......
SHORT REPORT--
- 2nd round of virus Europe
Carnival -3% after filing to sell up to $1B worth of shares
Sep. 15, 2020 7:23 AM ET| Talk about bad timing.
Carnival(NYSE:
CCL)discloses that it entered into a $1B equity distribution agreement with JPMorgan, Goldman Sachs, Bank of America and other firms.